EP1800689A4 - Liquid preparation of physiologically active peptide - Google Patents
Liquid preparation of physiologically active peptideInfo
- Publication number
- EP1800689A4 EP1800689A4 EP05774895A EP05774895A EP1800689A4 EP 1800689 A4 EP1800689 A4 EP 1800689A4 EP 05774895 A EP05774895 A EP 05774895A EP 05774895 A EP05774895 A EP 05774895A EP 1800689 A4 EP1800689 A4 EP 1800689A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- physiologically active
- liquid preparation
- active peptide
- peptide
- physiologically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004244339 | 2004-08-24 | ||
PCT/JP2005/015362 WO2006022301A1 (en) | 2004-08-24 | 2005-08-24 | Liquid preparation of physiologically active peptide |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1800689A1 EP1800689A1 (en) | 2007-06-27 |
EP1800689A4 true EP1800689A4 (en) | 2009-09-23 |
EP1800689B1 EP1800689B1 (en) | 2016-12-28 |
Family
ID=35967510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05774895.6A Active EP1800689B1 (en) | 2004-08-24 | 2005-08-24 | Liquid preparation of physiologically active peptide |
Country Status (11)
Country | Link |
---|---|
US (2) | US20080193997A1 (en) |
EP (1) | EP1800689B1 (en) |
JP (1) | JP4951344B2 (en) |
KR (1) | KR101149454B1 (en) |
CN (1) | CN101022822B (en) |
AU (1) | AU2005275779B2 (en) |
BR (1) | BRPI0514408B8 (en) |
CA (1) | CA2576473C (en) |
ES (1) | ES2620326T3 (en) |
IL (1) | IL181348A (en) |
WO (1) | WO2006022301A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080003220A1 (en) * | 2006-04-21 | 2008-01-03 | Amgen, Inc. | Buffering agents for biopharmaceutical formulations |
KR101466933B1 (en) | 2006-07-11 | 2014-12-01 | 큐피에스 엘엘씨 | Pharmaceutical compositions for sustained release delivery of peptides |
ES2672902T3 (en) | 2010-02-24 | 2018-06-18 | Arecor Limited | Protein formulations |
JP6118251B2 (en) * | 2011-08-25 | 2017-04-19 | 株式会社Lsiメディエンス | Method for measuring glucagon-like peptide-1 and kit used therefor |
US20150011473A1 (en) * | 2012-01-20 | 2015-01-08 | Lupin Limited | Stabilized pth formulation |
CN103301058A (en) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | Composition for teriparatide injection, and preparation method and preparation thereof |
EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
EP3685850A4 (en) | 2017-09-22 | 2021-06-16 | Asahi Kasei Pharma Corporation | Teriparatide-containing liquid pharmaceutical composition having excellent pharmacodynamics and/or stability |
JP6577683B2 (en) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | Liquid pharmaceutical composition containing teriparatide having excellent stability |
CN116718762A (en) * | 2023-06-09 | 2023-09-08 | 上海品峰医疗科技有限公司 | Polypeptide sample stabilizer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB770075A (en) * | 1954-03-15 | 1957-03-13 | Cutter Lab | Improvements in or relating to preparation of a fibrinogen product and stable solutions thereof |
WO1993019776A1 (en) * | 1992-04-03 | 1993-10-14 | Kabi Pharmacia Ab | Protein formulation comprising growth hormone |
WO1998028007A1 (en) * | 1996-12-24 | 1998-07-02 | Biogen, Inc. | Stable liquid interferon formulations |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0651637B2 (en) | 1985-03-28 | 1994-07-06 | エーザイ株式会社 | Peptide adsorption prevention composition |
JPH0669956B2 (en) | 1988-09-30 | 1994-09-07 | 旭化成工業株式会社 | Anti-adsorption agent for polypeptides |
JPH032136A (en) | 1989-05-30 | 1991-01-08 | Asahi Glass Co Ltd | Production of double metal cyanide complex and use thereof |
JPH0397083A (en) | 1989-09-08 | 1991-04-23 | Tokyo Electric Co Ltd | Label issuing device |
DE4126983A1 (en) | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | METHOD FOR THE PRODUCTION OF HUMAN-PROTEIN-CONTAINING, PRESERVED MEDICAMENTS FOR INFUSION OR INJECTION USE |
SE9300105D0 (en) * | 1993-01-15 | 1993-01-15 | Kabi Pharmacia Ab | STABLE PROTEIN SOLUTION |
US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
DE4340781C3 (en) * | 1993-11-30 | 2000-01-27 | Novartis Ag | Liquid preparations containing cyclosporin and process for their preparation |
TW426523B (en) * | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
US5780431A (en) * | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
US6440930B1 (en) * | 1998-09-17 | 2002-08-27 | Eli Lilly And Company | Protein formulations |
US20020061838A1 (en) * | 2000-05-17 | 2002-05-23 | Barton Holmquist | Peptide pharmaceutical formulations |
AU785444B2 (en) * | 2000-05-19 | 2007-06-14 | Jefferson Pharmaceuticals, Llc | Peptide pharmaceutical formulations |
CA2411667A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co. Inc. | Ghrelin analogs |
ATE382057T1 (en) * | 2001-06-28 | 2008-01-15 | Novo Nordisk As | STABLE FORMULATION OF MODIFIED GLP-1 |
IL162796A0 (en) | 2002-05-21 | 2005-11-20 | Kenji Kangawa | Medicinal compositions containing ghrelin |
EP1407779A1 (en) * | 2002-10-10 | 2004-04-14 | Gastrotech A/S | Use of ghrelin for treating low body weight and body fat in gastrectomized individuals |
-
2005
- 2005-08-24 WO PCT/JP2005/015362 patent/WO2006022301A1/en not_active Application Discontinuation
- 2005-08-24 KR KR1020077006467A patent/KR101149454B1/en active IP Right Grant
- 2005-08-24 US US11/660,406 patent/US20080193997A1/en not_active Abandoned
- 2005-08-24 JP JP2006531949A patent/JP4951344B2/en active Active
- 2005-08-24 BR BRPI0514408A patent/BRPI0514408B8/en not_active IP Right Cessation
- 2005-08-24 ES ES05774895.6T patent/ES2620326T3/en active Active
- 2005-08-24 CN CN2005800285946A patent/CN101022822B/en active Active
- 2005-08-24 AU AU2005275779A patent/AU2005275779B2/en active Active
- 2005-08-24 EP EP05774895.6A patent/EP1800689B1/en active Active
- 2005-08-24 CA CA2576473A patent/CA2576473C/en active Active
-
2007
- 2007-02-15 IL IL181348A patent/IL181348A/en active IP Right Grant
-
2010
- 2010-08-02 US US12/848,638 patent/US8969298B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB770075A (en) * | 1954-03-15 | 1957-03-13 | Cutter Lab | Improvements in or relating to preparation of a fibrinogen product and stable solutions thereof |
WO1993019776A1 (en) * | 1992-04-03 | 1993-10-14 | Kabi Pharmacia Ab | Protein formulation comprising growth hormone |
WO1998028007A1 (en) * | 1996-12-24 | 1998-07-02 | Biogen, Inc. | Stable liquid interferon formulations |
Non-Patent Citations (1)
Title |
---|
See also references of WO2006022301A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1800689B1 (en) | 2016-12-28 |
BRPI0514408B1 (en) | 2021-02-23 |
CN101022822A (en) | 2007-08-22 |
IL181348A (en) | 2014-06-30 |
US20080193997A1 (en) | 2008-08-14 |
BRPI0514408A (en) | 2008-06-10 |
JP4951344B2 (en) | 2012-06-13 |
JPWO2006022301A1 (en) | 2008-05-08 |
BRPI0514408B8 (en) | 2021-05-25 |
CA2576473C (en) | 2015-06-30 |
CA2576473A1 (en) | 2006-03-02 |
IL181348A0 (en) | 2007-07-04 |
AU2005275779A1 (en) | 2006-03-02 |
AU2005275779B2 (en) | 2011-09-15 |
EP1800689A1 (en) | 2007-06-27 |
WO2006022301A1 (en) | 2006-03-02 |
US8969298B2 (en) | 2015-03-03 |
CN101022822B (en) | 2012-06-27 |
ES2620326T3 (en) | 2017-06-28 |
KR20070057850A (en) | 2007-06-07 |
KR101149454B1 (en) | 2012-05-25 |
US20110077195A1 (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL181348A0 (en) | Liquid preparation of physiologically active peptide | |
PL1817048T3 (en) | Stable formulations of insulinoptropic peptides | |
TWI366443B (en) | Delivery of functional ingredients | |
IL183252A0 (en) | Solid formulations of liquid biologically active agents | |
HUE039142T2 (en) | Fungicidal combinations of active ingredients | |
HK1181633A1 (en) | Endoscopic delivery of medical devices | |
EP1758617A4 (en) | Stable liquid and lyophilized formulation of proteins | |
EP1785131A4 (en) | External preparation of s/o type | |
EP1942981A4 (en) | Delivery of agents to tissue | |
EP1804823A4 (en) | Novel cyclosporin analogues and their pharmaceutical uses | |
ZA200705750B (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
AU2003252299A8 (en) | Novel physiologically active substance | |
EP1721604A4 (en) | Stable capsule preparation | |
GB0524958D0 (en) | Transdermal administration of active agents | |
EP1961764A4 (en) | Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient | |
ZA200706095B (en) | Therapeutic formulations of keratinocyte growth factor | |
EP1948676A4 (en) | Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same | |
EP1548121A4 (en) | Novel physiologically active substances | |
EP1740541A4 (en) | Therapeutic formulations of desoxyepothilones | |
GB2431878B (en) | Container of active substances | |
IL179697A0 (en) | Variants of unc5h2, their preparation and pharmaceutical compositions containing them | |
PL2026879T3 (en) | Use of peptides as active slimming ingredients | |
HK1122731A1 (en) | Prolonged release formulation of active pharmaceutical ingredients | |
EP1767210A4 (en) | The medical use of paeoniflorin | |
EP1714976A4 (en) | Amino acid sequences from active principle of musk and their acetic salt, also the preparation and usage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20070213 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ASUBIO PHARMA CO., LTD. Owner name: KANGAWA, KENJI |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090824 |
|
17Q | First examination report despatched |
Effective date: 20091218 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DAIICHI SANKYO COMPANY, LIMITED Owner name: KANGAWA, KENJI |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602005051017 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0038040000 Ipc: A61K0038250000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/26 20060101ALI20151126BHEP Ipc: A61K 9/00 20060101ALI20151126BHEP Ipc: A61K 47/40 20060101ALI20151126BHEP Ipc: A61K 47/22 20060101ALI20151126BHEP Ipc: A61K 47/10 20060101ALI20151126BHEP Ipc: A61K 38/25 20060101AFI20151126BHEP Ipc: A61K 47/12 20060101ALI20151126BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160113 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160506 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
GRAR | Information related to intention to grant a patent recorded |
Free format text: ORIGINAL CODE: EPIDOSNIGR71 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
INTG | Intention to grant announced |
Effective date: 20161117 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 856740 Country of ref document: AT Kind code of ref document: T Effective date: 20170115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602005051017 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170329 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20161228 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 856740 Country of ref document: AT Kind code of ref document: T Effective date: 20161228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2620326 Country of ref document: ES Kind code of ref document: T3 Effective date: 20170628 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170428 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170328 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170428 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602005051017 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 |
|
26N | No opposition filed |
Effective date: 20170929 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170824 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170824 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20050824 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161228 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230711 Year of fee payment: 19 Ref country code: GB Payment date: 20230706 Year of fee payment: 19 Ref country code: ES Payment date: 20230901 Year of fee payment: 19 Ref country code: CH Payment date: 20230902 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230703 Year of fee payment: 19 Ref country code: DE Payment date: 20230627 Year of fee payment: 19 |